Adhérent PreciDIAB : Bayer

Bayer is an international Life Sciences group, whose core businesses are health and agriculture. Bayer’s products and services are designed to meet the challenges of a growing and aging global population, protecting everyone every day. Creating value through innovation and science, Bayer is strongly committed to sustainable development and adopts transparent and responsible conduct in its activities. In 2020, Bayer had nearly 100,000 employees and generated sales of 41.4 billion euros. The Group spent 4.9 billion euros on R&D.

Bayer’s Pharmaceuticals Division provides healthcare professionals and patients with prescription drugs for the therapeutic areas of cardiology, oncology, women’s health, hematology and ophthalmology as well as radiology. By enabling the diagnosis and treatment of diseases, as well as the development of digital solutions to optimize the patient’s care path, Bayer is working for greater well-being and an improvement in the quality of life of patients.

Bayer, as a recognized player in the care of patients with cardiovascular pathologies, aims to contribute more widely to improving the care of patients at risk of developing complications, particularly in the context of of their diabetes. The PreciDIAB Initiative fits perfectly into the positioning we must have to support the molecules in our pipeline through large-scale partnerships!